Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The firm presently has a $83.00 target price on the pharmaceutical company’s stock. Zacks Investment Research’s price objective would indicate a potential upside of 11.69% from the company’s previous close. […]
